Select Page

PsychoGenics Obtains Funding For Their High Throughput CNS Drug Discovery Platform

Hawthorne, New York, August 28, 2002, PsychoGenics Inc. announced today that its application to the National Institute of Mental Health of the National Institutes of Health for a fast-track (Phase I and II) Small Business Innovation Research (SBIR) grant, totaling $1,062,158, has been approved. The grant will help support the further development of SmartCubeTM, the first proprietary high-throughput system for testing behavior and physiology in live animals (in vivo). SmartCubeTM combines the company’s expertise in behavioral pharmacology with innovations in robotics, computer vision and bioinformatics, bringing massively parallel data acquisition and analysis to the study of behavior and a new approach to the central nervous system (CNS) drug discovery.